Clinical trials: Digestive System Malignancies
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01624285
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 21 sites in United States
- Volunteers
- 73 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rectal Cancer, Colon Cancer
Perfusion Assessment in Laparoscopic Left Anterior Resection
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic…
- Conditions
- Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp
- Trial name
- PILLAR II (NCT01560377)
- Testing
- PINPOINT Endoscopic Fluorescence Imaging System
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Metastatic Colorectal Cancer
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard…
- Trial name
- 379 (NCT03791398)
- Testing
- Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Brown University
Colon Cancer, Rectal Cancer
Genistein in Treatment of Metastatic Colorectal Cancer
Colorectal neoplasms are the third most common malignancies in the United States. Patients with metastatic (stage IV) colorectal cancer have a median life expectancy of 2 years.
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- NCT01985763
- Testing
- Genistein
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sofya Pintova
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Colon Cancer
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
In this research study, investigators use colonoscopy as a case example to evaluate a predictive overbooking model derived using patient-level predictors of absenteeism.
- Trial name
- No-show (NCT01639443)
- Testing
- Predictive no-show overbooking
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
- Trial name
- NCT01594125
- Testing
- Nintedanib high dose, Nintedanib low dose, Nintedanib medium dose
- Where
- 5 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Rectum Cancer
Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery
To evaluate the influence to the blood supply of the anastomosis and the harvest of the No. 253 lymph nodes in different surgical methods--- preserving the left colic artery (LCA) and resect the No.
- Trial name
- POTLCAORCS (NCT01979029)
- Testing
- preserving the left colic artery, not preserving the left colic artery
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Jian Suo
Pancreatic Pseudocyst(s)
AXIOS Stent & Delivery System Study
The Xlumena AXIOS Stent and Delivery System is an investigational device in the USA, and this study is being conducted under an Investigational Device Exemption (IDE) granted by the US Food and Drug Administration (FDA).
- Trial name
- NCT01419769
- Testing
- AXIOS Stent & Delivery System
- Where
- 7 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- Xlumena, Inc.
Advanced Hepatocellular Carcinoma
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered…
- Trial name
- NCT02795429
- Testing
- Spartalizumab, Capmatinib
- Where
- 17 sites in Canada, China and 6 more
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical…
- Trial name
- NCT00682786
- Testing
- 5FU, Radiation, Surgery of resectable lesions
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Washington University School of Medicine
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places.
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7
- Trial name
- NCT02873195
- Testing
- Atezolizumab, Bevacizumab, Capecitabine
- Where
- 10 sites in United States
- Volunteers
- 133 people
- Sponsor
- Academic and Community Cancer Research United
Liver Cancer
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
The purpose of this study is to determine the response of liver tumors to radiation therapy using Tomotherapy.
- Trial name
- NCT01030757
- Testing
- Tomotherapy treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New Mexico Cancer Research Alliance
Colorectal Cancer, Pancreas Cancer
Maintenance Dovitinib for Colorectal and Pancreas Cancer
This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had surgery to remove metastases and patients with pancreas cancer, which has been surgically removed and are receiving adjuvant…
- Trial name
- NCT01888965
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Pancreatic Cancer, Cancer of the Pancreas
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
- Trial name
- NCT04536077
- Testing
- CDX-301, CDX-1140, Research blood draw
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.